

Efineptakin alfa

Cat. No.:	HY-P99908
CAS No.:	2026634-47-7
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 ⁺ and CD8 ⁺ cells in both human and mice. Efineptakin alfa can be used for glioblastoma research ^[1] .								
IC₅₀ & Target	IL7R								
In Vivo	<p>Efineptakin alfa (10 mg/kg, IM, single) combined with SLC-3010 (1.8 mg/kg, IV, single) inhibits tumor growth in MC38-bearing mice^[1].</p> <p>Efineptakin alfa (10 mg/kg) mitigates RT-related lymphopenia, increases cytotoxic CD8 T lymphocytes systemically and in the tumor, and improves survival in orthotopic glioma-bearing mice^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57BL/6 mice bearing intracranial tumors (GL261 or CT2A)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>On the final day of RT (radiotherapy, 1.8 Gy/day × 5 days) completion</td> </tr> <tr> <td>Result:</td> <td>Increased T lymphocytes in the lymph nodes, thymus, and spleen, enhanced IFNγ production, and decreased Tregs in the tumor which was associated with a significant increase in survival. Enhanced central memory and effector memory CD8 T cells in lymphoid organs and tumor. Decreased progenitor cells in the bone marrow.</td> </tr> </table>	Animal Model:	C57BL/6 mice bearing intracranial tumors (GL261 or CT2A) ^[1]	Dosage:	10 mg/kg	Administration:	On the final day of RT (radiotherapy, 1.8 Gy/day × 5 days) completion	Result:	Increased T lymphocytes in the lymph nodes, thymus, and spleen, enhanced IFN γ production, and decreased Tregs in the tumor which was associated with a significant increase in survival. Enhanced central memory and effector memory CD8 T cells in lymphoid organs and tumor. Decreased progenitor cells in the bone marrow.
Animal Model:	C57BL/6 mice bearing intracranial tumors (GL261 or CT2A) ^[1]								
Dosage:	10 mg/kg								
Administration:	On the final day of RT (radiotherapy, 1.8 Gy/day × 5 days) completion								
Result:	Increased T lymphocytes in the lymph nodes, thymus, and spleen, enhanced IFN γ production, and decreased Tregs in the tumor which was associated with a significant increase in survival. Enhanced central memory and effector memory CD8 T cells in lymphoid organs and tumor. Decreased progenitor cells in the bone marrow.								

REFERENCES

[1]. Campian JL, et al. Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. Clin Cancer Res. 2022 Mar 15;28(6):1229-1239.

[2]. Seungtae Baek, et al. rhIL-7-hyFc (efineptakin alfa; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex. 2022 AACR Abstract #4199.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA